BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 24625697)

  • 21. Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition.
    Tolbert S; Liu Y; Hellegers C; Petrella JR; Weiner MW; Wong TZ; Murali Doraiswamy P
    J Prev Alzheimers Dis; 2019; 6(4):274-282. PubMed ID: 31686100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.
    Klinger RY; James OG; Borges-Neto S; Bisanar T; Li YJ; Qi W; Berger M; Terrando N; Newman MF; Doraiswamy PM; Mathew JP; ;
    Anesthesiology; 2018 Apr; 128(4):728-744. PubMed ID: 29389750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.
    Huang SY; Zhang YR; Guo Y; Du J; Ren P; Wu BS; Feng JF; ; Cheng W; Yu JT
    Alzheimers Dement; 2024 May; 20(5):3251-3269. PubMed ID: 38501315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer's Dementia Using the NACC Database.
    Liu Y; Chan DK; Crawford JD; Sachdev PS; Braidy N
    Curr Alzheimer Res; 2020; 17(13):1167-1176. PubMed ID: 33583381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
    Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of T
    Boles Ponto LL; Magnotta VA; Menda Y; Moser DJ; Oleson JJ; Harlynn EL; DeVries SD; Wemmie JA; Schultz SK
    J Neuropsychiatry Clin Neurosci; 2020; 32(4):352-361. PubMed ID: 32283991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
    Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
    Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
    Vannini P; Amariglio R; Hanseeuw B; Johnson KA; McLaren DG; Chhatwal J; Pascual-Leone A; Rentz D; Sperling RA
    Neuropsychologia; 2017 May; 99():343-349. PubMed ID: 28385579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau-related grey matter network breakdown across the Alzheimer's disease continuum.
    Pelkmans W; Ossenkoppele R; Dicks E; Strandberg O; Barkhof F; Tijms BM; Pereira JB; Hansson O
    Alzheimers Res Ther; 2021 Aug; 13(1):138. PubMed ID: 34389066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
    Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
    J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.
    Teipel S; Heinsen H; Amaro E; Grinberg LT; Krause B; Grothe M;
    Neurobiol Aging; 2014 Mar; 35(3):482-91. PubMed ID: 24176625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress of Brain Amyloid Deposition in Familial Alzheimer's Disease with Taiwan D678H APP Mutation.
    Weng YC; Hsiao IT; Huang CY; Huang KL; Liu CH; Chang TY; Yen TC; Lin KJ; Huang CC
    J Alzheimers Dis; 2018; 66(2):775-787. PubMed ID: 30320594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.